Table 2.
Approach | Description | Protein and accumulation 1 | Component | References |
---|---|---|---|---|
Protease inhibitor | Co‐expression with protease inhibitors | C5‐1 IgG antibody (LC; 70–80%) | SlCDI; SlCYS9 | Goulet et al. (2012) |
C5‐1 IgG antibody (HC; 85%) | SlCDI | Goulet et al. (2012) | ||
C5‐1 IgG antibody (40%) | SlCYS8 | Robert et al. (2013) | ||
H10 IgG antibody (HC; 7.5‐fold) | SlCYS8 | Jutras et al. (2016) | ||
α‐Galactosidase (4–14%) Erythropoietin (16‐ to 27‐fold) VRC01 IgG antibody (2‐ to 10‐fold) |
NbPR4, NbPot1 & HsTIMP | Grosse‐Holz et al. (2018b) | ||
Protease knockdown/out | RNAi and gene editing | CAP256 IgG antibody (−) | NbVPE‐1a, NbVPE‐1b, and NbCysP6 | Singh et al. (2022) |
Recombinant protein compartmentation | Retention to ER or storage in protein bodies; vacuolar targeting | Fungal xylanase xyn11A (10‐fold) | HFBI | Saberianfar et al. (2015) |
Erythropoietin (twofold) | ELP | Saberianfar et al. (2015) | ||
Erythropoietin (twofold) | HFBI | Saberianfar et al. (2015) | ||
Interleucin‐10 (threefold) | HFBI |
Saberianfar et al. (2015) |
||
14D9 IgG antibody (10‐ to 15‐fold) | ER; vacuole | Ocampo et al. (2016) | ||
pH modulation of the plant secretory pathway | Co‐expression with proton channels | α1‐antichymotrypsin (fivefold) | Influenza M2 ion channel | Jutras et al. (2015, 2018) |
H3 influenza A (increase; ns) | ||||
HA influenza B (increase; ns) |
ELP, elastin‐like polypeptide; H, hemagglutinin; HFBI, hydrophobin; VPE, vacuolar processing enzymes.
Approximate accumulation according to authors' statements, − indicates no significant change, n/s indicates not specified.